Intellia Therapeutics (NTLA) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free NTLA Stock Alerts $24.46 -0.40 (-1.61%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIntellia Therapeutics (NASDAQ:NTLA) Raised to "Sell" at StockNews.commarketbeat.com - May 11 at 12:16 AMIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $29.00 at Citigroupmarketbeat.com - May 10 at 6:57 PMBarclays Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)markets.businessinsider.com - May 10 at 6:44 PMBMO Capital Markets Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00marketbeat.com - May 10 at 12:19 PMCathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com - May 10 at 11:45 AMAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)markets.businessinsider.com - May 10 at 9:51 AMIntellia Therapeutics First Quarter 2024 Earnings: Beats Expectationsfinance.yahoo.com - May 10 at 9:51 AMNTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024msn.com - May 9 at 6:48 PMIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $23.00marketbeat.com - May 9 at 1:36 PMIntellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progressfinanznachrichten.de - May 9 at 9:35 AMCrispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergseekingalpha.com - May 9 at 9:35 AMIntellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progressglobenewswire.com - May 9 at 7:30 AMIntellia Therapeutics (NTLA) Scheduled to Post Quarterly Earnings on Thursdayamericanbankingnews.com - May 8 at 5:10 AM265,981 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vestmark Advisory Solutions Inc.marketbeat.com - May 5 at 6:26 PMShhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radarinvestorplace.com - May 3 at 2:18 PMIntellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - May 3 at 9:44 AMIntellia Therapeutics Inc (NTLA) Earnings Dates & Reportsinvesting.com - May 3 at 8:24 AMIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updatesfinance.yahoo.com - May 2 at 12:16 PMIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updatesglobenewswire.com - May 2 at 7:30 AM3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaireinvestorplace.com - May 2 at 6:04 AMInvest In A Revolutionary Gene Therapy With CRISPR Therapeuticsseekingalpha.com - April 30 at 2:20 PMIntellia Therapeutics (NASDAQ:NTLA) Trading Up 6.8%marketbeat.com - April 29 at 4:35 PMIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024globenewswire.com - April 29 at 7:30 AMabrdn plc Buys New Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 28 at 5:29 AMIntellia Therapeutics Inc (NTLA)investing.com - April 27 at 12:24 AMIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low at $19.77marketbeat.com - April 25 at 3:44 PMIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?finance.yahoo.com - April 25 at 2:55 PMIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbushmarketbeat.com - April 23 at 1:49 PMFederated Hermes Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 20 at 6:58 AMSumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 17 at 6:09 AMIntellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low at $22.51marketbeat.com - April 15 at 5:31 PMMirae Asset Global Investments Co. Ltd. Sells 100,885 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 15 at 5:17 AMCapital Advisors Inc. OK Acquires 73,379 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 13 at 5:00 PMCathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.fool.com - April 12 at 4:50 AMBull Market and Beyond: 3 Stocks Just Waiting to Soarfool.com - April 9 at 4:50 AMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - April 5 at 6:36 AMIntellia Therapeutics (NASDAQ:NTLA) Shares Down 7.1% marketbeat.com - April 2 at 5:45 PMSmart Money Is Betting Big In NTLA Optionsbenzinga.com - March 28 at 8:07 PMARK Investment Management LLC Grows Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - March 28 at 6:39 AMBetter Cathie Wood Stock: Moderna vs. Intelliafool.com - March 28 at 5:55 AMIntellia Therapeutics Ends Co-Development Agreement With Regeneronmarketwatch.com - March 22 at 6:12 PMIntellia opts out of hemophilia pact with Regeneronmsn.com - March 22 at 6:12 PMHot Stocks: The 3 Best Opportunities for Investing in Biotechinvestorplace.com - March 21 at 5:29 PM3 Stocks That Could Be the Next Big Thing in Gene Editinginvestorplace.com - March 21 at 4:19 PMIntellia begins phase 3 trial for CRISPR therapy NTLA-2001investing.com - March 20 at 5:25 PMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Increased by Wellington Management Group LLPmarketbeat.com - March 19 at 4:53 AMIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathyglobenewswire.com - March 18 at 7:30 AMIntellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6%marketbeat.com - March 12 at 1:24 PMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - March 11 at 6:17 AMIs Intellia Therapeutics Stock a Buy Now?fool.com - March 9 at 9:45 AM Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here NTLA Media Mentions By Week NTLA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.390.58▲Average Medical News Sentiment NTLA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼184▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Celldex Therapeutics News Myriad Genetics News Neogen News QuidelOrtho News Editas Medicine News Cellectis News Sangamo Therapeutics News CRISPR Therapeutics News Lantheus News Kymera Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
